Alkermes CEO Richard Pops to Retire; COO Blair Jackson Appointed Successor
ALKS sits 29% above its 52-week low of $25.165 on light trading volume (0.1× avg).
Summary
After 35 years, Richard Pops will retire as CEO of Alkermes plc, effective July 31, 2026, with current COO Blair Jackson stepping into the role on August 1, 2026. Pops will remain non-executive Chairman.
Key Events · Executive and Board Changes · ALKS
-
CEO Retirement Announced
Richard F. Pops will retire from his position as Chief Executive Officer of Alkermes plc, effective July 31, 2026, following 35 years of service in the role.
-
New CEO Appointed
Blair C. Jackson, currently the company's Executive Vice President and Chief Operating Officer, has been appointed to serve as Chief Executive Officer, effective August 1, 2026.
-
Pops to Remain Chairman and Advisor
Mr. Pops will continue to serve as non-executive Chairman of the Board and as a Senior Advisor to the company through December 31, 2026, facilitating a smooth transition.
-
Transition Compensation Details
Mr. Pops' continued service includes a monthly cash retainer of $75,000, a pro-rated 2026 annual cash bonus, a time-based restricted stock unit award, and an annual retainer for his non-executive Chairman role.
Analysis · ALKS · Life Sciences
This 8-K announces a significant leadership transition for Alkermes plc, with long-serving CEO Richard Pops retiring after 35 years. The appointment of current COO Blair Jackson as his successor, coupled with Mr. Pops remaining as non-executive Chairman and Senior Advisor, signals a planned and orderly transition. This internal promotion suggests continuity in strategy, which may reassure investors following the company's recent acquisition of Avadel Pharmaceuticals and its latest earnings report. The structured handover aims to maintain stability and leverage existing leadership expertise during this period of change.
At the time of this filing, ALKS was trading at $32.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $25.17 to $36.32. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.